Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial
- 25 July 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
Abstract
Background: High-grade central nervous system (CNS) tumors carry a poor prognosis with limited curative options if first-line therapy fails. B7-H3 is expressed in many of these tumors, and chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapeutic strategy. Methods: BrainChild-03 (NCT04185038) is a single-center, dose-escalation phase 1 study of repeated intracerebroventricular (ICV) B7-H3 CAR T cells in children and young adults with recurrent/refractory CNS tumors (Arms A and B) and diffuse intrinsic pontine glioma (Arm C). Here, we report results from Arm B, in which patients with refractory/relapsed CNS tumors or pre- or post-progression non-pontine diffuse midline glioma (DMG) received repeated ICV infusions. Primary objectives were feasibility and safety/tolerability; secondary objectives included CAR T cell detection, disease response, and survival. Results: Of 36 enrolled patients (atypical teratoid rhabdoid tumor n = 5, DMG n = 8, embryonal tumor with multilayer rosettes n = 2, ependymoma n = 4, high-grade glioma n = 6, medulloblastoma n = 8, pineoblastoma n = 3), manufacturing was successful for 35 patients, 26 of whom received therapy. Median age was 10 years (range 1-26). Dose escalation from 1 × 107 to 10 × 107 CAR T cells/dose identified this dose as the maximally tolerated dose regimen, with no dose-limiting toxicities observed. Across 181 total doses (median 7/patient), common adverse events included headache (n = 26), fever (n = 15), and nausea (n = 14). Median survival from first infusion was 11.5 months, ranging from 3.2 months (pineoblastoma, high-grade glioma) to 21.4 months (ependymoma); 2 patients achieved a partial response. Conclusions: Repeated ICV B7-H3 CAR T cell dosing is feasible and tolerable across a spectrum of pediatric CNS tumors, supporting continued investigation in future trials.Keywords
Funding Information
- The Avery Huffman DIPG Foundation
- McKenna Claire Foundation
- Pediatric Brain Tumor Research Fund Guild of Seattle Children’s, Team Cozzi Foundation
- Unravel Pediatric Cancer
- DIPG/DMG Research Funding Alliance
- Connie Foundation
- Yuvaan Tiwari Foundation
- Cancer Dream Team Translational Cancer Research Grants (SU2C-AACR-DT-27-17)
- Entertainment Industry Foundation
- American Association for Cancer Research
- National Cancer Institute
- National Institutes of Health (R37CA289981)
This publication has 30 references indexed in Scilit:
- Pediatric Central Nervous System Embryonal Tumors: Presentation, Diagnosis, Therapeutic Strategies, and Survivorship—A ReviewPediatric Neurology, 2024
- CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trialsCancer and Metastasis Reviews, 2024
- Prognostic factors analysis of diffuse midline gliomaJournal of Neuro-Oncology, 2024
- Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safetyNeoplasia, 2023
- Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in ManagementNeurotherapeutics, 2022
- Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastomaSignal Transduction and Targeted Therapy, 2021
- Engineering and Design of Chimeric Antigen ReceptorsMolecular Therapy - Methods & Clinical Development, 2019
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupThe Lancet Oncology, 2015
- Relapse patterns in pediatric embryonal central nervous system tumorsJournal of Neuro-Oncology, 2013
- B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine gliomaJournal of Neuro-Oncology, 2012